How Do You Build A Clinical Trial Network Focused On Diversity?
Executive Summary
Stakeholders discuss network models, barriers to their creation, and what is needed for them to be successful at PhRMA meeting.
You may also be interested in...
Has There Been A Sea Change In Trial Diversity Efforts?
PhRMA partnered with Deloitte to produce a report that included a survey of 31 member companies indicating that most had made significant investments in improving clinical trial diversity.
Clinical Trial Diversity: Data Points to Structural, Not Patient-Specific Solutions
Minorities are more likely to participate in cancer clinical trials than white people, but they are less likely to get the chance to say yes, highlighting the importance of bringing studies to different locations if sponsors are to be successful at increasing diversity.
Reducing Clinical Trial Burdens Brings Greater Participant Diversity – PhRMA
Industry principles for enhancing diversity in clinical trials call for use of digital data collection tools and flexible scheduling of study site visits to reduce barriers to enrollment, as well as greater involvement of under-represented communities in the trial design planning process and recruitment of investigators with diverse ethnic and racial backrounds.